| Literature DB >> 29949594 |
Sasisopin Kiertiburanakul1, Pawinee Wongprasit2, Angsana Phuphuakrat1, Darunee Chotiprasitsakul1, Somnuek Sungkanuparph1.
Abstract
BACKGROUND: Health care providers usually focus on index HIV-infected patients and seldom obtain information from their partners. We aimed to determine HIV-preventative measures among couples, the prevalence of HIV infection, and treatment outcomes of partners.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29949594 PMCID: PMC6021083 DOI: 10.1371/journal.pone.0198654
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flowchart.
aadherence, adverse drug reaction, CD4 count, and HIV RNA; badherence < 95%, had adverse drug reaction, or detectable HIV RNA (> 200 copies/mL) in the prior 6 months; cHIV prevention and adherence counselling; repeated HIV RNA and/or HIV genotype (if HIV RNA > 1,000 copies/mL).
Clinical characteristics and laboratory investigations of the 393 index HIV-infected patients.
| Variables | Index patients in serodiscordant couples | Index patients in seroconcordant couples | |
|---|---|---|---|
| Male, n (%) | 67 (43.0) | 123 (51.9) | 0.082 |
| Median (IQR) age, years | 39.4 | 41.9 | < 0.001 |
| HIV risk, n (%) | 0.681 | ||
| Heterosexual | 149 (95.5) | 221 (93.2) | |
| Men who have sex with men | 5 (3.2) | 12 (5.1) | |
| Others | 2 (1.3) | 4 (1.7) | |
| Presence of co-morbidity, n (%) | 45 (28.8) | 82 (34.6) | 0.233 |
| Presence of AIDS-defining illness, n (%) | 48 (30.8) | 105 (44.3) | 0.007 |
| Median (IQR) nadir CD4 count, cells/mm3 | 132 (40–303) | 94 (33–238) | 0.088 |
| HBsAg, n (%) | 0.273 | ||
| Negative | 107 (68.6) | 146 (61.6) | |
| Positive | 9 (5.8) | 22 (9.3) | |
| Not tested | 40 (25.6) | 69 (29.1) | |
| Anti-HCV, n (%) | 0.169 | ||
| Negative | 102 (65.4) | 133 (56.1) | |
| Positive | 3 (1.9) | 8 (3.4) | |
| Not tested | 51 (32.7) | 96 (40.5) | |
| VDRL, n (%) | 0.022 | ||
| Negative | 104 (66.7) | 130 (54.8) | |
| Positive | 2 (1.3) | 12 (5.1) | |
| Not tested | 50 (32.0) | 95 (40.1) |
IQR, interquartile range; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; VDRL, Venereal Disease Research Laboratory
Clinical characteristics and laboratory investigations of the 393 partners.
| Variables | HIV-uninfected | HIV-infected | |
|---|---|---|---|
| Male, n (%) | 94 (60.3) | 124 (52.3) | 0.121 |
| Median (IQR) age, years | 38.4 | 41.6 | 0.024 |
| Receiving care at the general hospital, n (%) | 91 (58.3) | 103 (43.5) | 0.004 |
| Presence of co-morbidity, n (%) | 39 (25.0) | 66 (27.8) | 0.532 |
| Presence of AIDS-defining illness, n (%) | - | 42 (17.7) | - |
| Median (IQR) nadir CD4 count, cells/mm3 | - | 240 (96–427) | - |
| HBsAg, n (%) | < 0.001 | ||
| Negative | 25 (16.0) | 138 (58.2) | |
| Positive | 2 (1.3) | 19 (8.0) | |
| Not tested | 129 (82.7) | 80 (33.8) | |
| Anti-HCV, n (%) | <0.001 | ||
| Negative | 17 (10.9) | 125 (52.7) | |
| Positive | 0 | 5 (2.1) | |
| Not tested | 139 (89.1) | 107 (45.2) | |
| VDRL, n (%) | <0.001 | ||
| Negative | 21 (13.5) | 124 (52.3) | |
| Positive | 0 | 3 (1.3) | |
| Not tested | 135 (86.5) | 110 (46.4) |
IQR, interquartile range; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; VDRL, Venereal Disease Research Laboratory
Fig 2Proportion of couples using condoms or abstaining from sex, stratified by the HIV serostatus of the partners.
Fig 3Proportion receiving antiretroviral therapy and outcomes of the index HIV-infected patients with serodiscordant, seroconcordant, and unknown HIV serostatus partners.
Index HIV-infected patient factors associated with serodiscordant relationships by multivariate logistic regression.
| Variables | Odds ratio | 95% CI | |
|---|---|---|---|
| Age, per 5 years decreased | 1.04 | 1.01–1.06 | 0.009 |
| Receiving care at the general hospital | 1.73 | 1.08–2.78 | 0.023 |
| Duration of the relationship, per year shorter | 1.04 | 1.01–1.07 | 0.003 |
| Nadir CD4 count, per 50 cells/mm3 increased | 1.06 | 1.01–1.13 | 0.029 |
| Did not receive PI-based regimen | 2.04 | 1.06–3.96 | 0.034 |
CI, confidence interval; PI, protease inhibitor